We are live on ! Find out more
HALO icon

Halozyme

409 hedge funds and large institutions have $4.61B invested in Halozyme in 2023 Q4 according to their latest regulatory filings, with 48 funds opening new positions, 146 increasing their positions, 144 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

291% more call options, than puts

Call options by funds: $18.9M | Put options by funds: $4.84M

37% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 35

14% more capital inflows, than outflows

Capital inflows: $378M | Capital outflows: $330M

6% more funds holding

Funds holding: 387 → 409 (+22)

1.02% more ownership

Funds ownership: 93.35% → 94.37% (+1%)

1% more repeat investments, than reductions

Existing positions increased: 146 | Existing positions reduced: 144

60% less funds holding in top 10

Funds holding in top 10: 5 → 2 (-3)

Holders
409
Holders Change
+22
Holders Change %
+5.68%
% of All Funds
5.95%
Holding in Top 10
2
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-60%
% of All Funds
0.03%
New
48
Increased
146
Reduced
144
Closed
35
Calls
$18.9​M
Puts
$4.84​M
Net Calls
+$14.1​M
Net Calls Change
-⁠$740​K

HALO Hedge Fund Activity: Q4 2023 in Review

409 of the 6,876 institutional investors tracked by Wall St. Rank reported a position in Halozyme (HALO) for Q4 2023, worth a combined $4.61B — down 2% from $4.71B a quarter earlier.

Buyers outnumbered sellers: 48 funds opened new HALO positions and 35 closed out — a net gain of 13 holders — while 146 added to existing stakes and 144 trimmed.

The largest buyer was TD Asset Management, adding an estimated $62.6M. The largest seller was Marshall Wace, cutting an estimated $78.3M.

  • 409 institutional investors held Halozyme (HALO) as of Q4 2023, up from 387 in Q3 2023.
  • Funds reported $4.61B of Halozyme stock for Q4 2023, down 2% quarter-over-quarter.
  • 48 funds opened new Halozyme positions in Q4 2023 and 35 closed out, a net change of +13 holders.
  • The largest Halozyme buyer in Q4 2023 was TD Asset Management, an estimated $62.6M added.
  • The largest Halozyme seller in Q4 2023 was Marshall Wace, an estimated $78.3M sold.

Based on aggregated 13F filings for Q4 2023.